For BRD9, we discovered that the survival time of patients with 3 cancer types was significantly shorted by high mRNA expression of BRD9: liver cancer (HR, 1.72; 95% CI, 1.21 to 2.46), ccRCC (HR, 1.54; 95% CI, 1.11 to 2.12), and sarcoma (HR, 1.78; 95% CI, 1.17 to 2.71) (Fig 4B). Here, BRD9 is linked to liver cancer.